Arcus Biosciences Q2 FY26 net loss widens to USD 91 million; revenue drops 74.38% to USD 41 million - RCUS News | RalliesArcus Biosciences Q2 FY26 net loss widens to USD 91 million; revenue drops 74.38% to USD 41 million
R
RCUS• Q2 FY26 financial results
- Arcus Biosciences posted a GAAP net loss of $91 million, or $0.72 a share, for Q2 2026.
- Revenue fell 74.38% to $41 million versus Q2 2025, on a $143 million prior-year catch-up tied to pausing etrumadenant.
- R&D expenses declined 18.71% to $113 million, while G&A costs dropped 17.24% to $24 million.
- Cash, cash equivalents and marketable securities were $775 million at June 30; Arcus forecast roughly $600 million at end-2026.
Pipeline and runway outlook
- Casdatifan ARC-20 readouts are due in H2 2026; Phase 3 PEAK-20 is expected to start by year-end, with cash runway into H2 2028.
•
